StockpollyBeta
Get App
Popularity #808
CI · NYSE · Medical - Healthcare Plans

Cigna (CI)

Combines pharmacy benefits and specialty care services with employer and international health coverage.

$273.42
vs last close−1.05 (−0.38%)
Loading prices…

Something off on this page? Send us feedback.

Cigna CorporationCI
Health Care

Sells pharmacy benefits, specialty-drug distribution, care management, and employer and international health coverage through Evernorth Health Services and Cigna Healthcare. Evernorth generates most revenue and serves third-party health plans, employers, government organizations, and providers alongside the insurance business.

Runs Evernorth Health Services and Cigna Healthcare as complementary health services and benefits businesses. Evernorth houses Express Scripts pharmacy benefits, Accredo specialty pharmacy, eviCore medical benefits management, specialty-drug distribution, behavioral health, and care delivery. It sells these capabilities to health plans, employers, government organizations, and providers beyond the insurance operation.

Provides U.S. employer medical, pharmacy, behavioral, dental, vision, and supplemental benefits through Cigna Healthcare, plus international plans. Operations are overwhelmingly U.S.-based. Combining benefit administration with home delivery and specialty-drug fulfillment, Evernorth generates most revenue. The sale of Medicare insurance and CareAllies narrowed the insurance portfolio, while Evernorth retained Medicare service agreements. Results depend on a major PBM client, medical and drug-cost management, and extensive insurance, pharmacy, ERISA, and PBM regulation.

Company facts

CEOBrian C. Evanko
ListedMar 31, 1982
ExchangeNYSE
HeadquartersBloomfield, CT
CountryUnited States
Employees67,700
CIK0001739940
ISINUS1255231003

Market cap$72.53B
EPS (ttm)$24.16
P/E (ttm)11.36
ROE15.2%
P/B1.70
P/S0.2568
Dividend yieldDiv yield2.26%
Beta0.19vs XLV 0.67

Price target$330.00+20.2%Average of 39 analysts
ConsensusBuy28 of 39 analysts
Ratings

Target rangeAs of Sep 21, 2026

Latest analyst notes

DateFirmActionPriorCurrent
Aug 4, 2026JefferiesDowngrade
Rating: BuyTarget: $330
Rating: HoldTarget: $307
Aug 3, 2026Raymond JamesDowngrade
Rating: Strong BuyTarget: $340
Rating: OutperformTarget: $320
Jul 31, 2026Robert W. BairdTarget
Target: $337
Target: $362
Jul 31, 2026GuggenheimReiterate
Rating: —Target: $318
Rating: BuyTarget: $361
Jul 31, 2026Wells FargoReiterate
Rating: —Target: $300
Rating: Equal WeightTarget: $307

Next report
Oct 29, 26
in 37 days
EPS estimate
$7.51
Revenue estimate
$72.65B
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Jan '25May '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$6.64$6.74$7.20$7.83$8.08$7.79$7.78Pending
Estimate$7.84$6.35$7.16$7.64$7.88$7.60$7.60$7.51
Surprise−15.3%+6.1%+0.6%+2.5%+2.5%+2.5%+2.4%—

RevenueReportedEstimate

Jan '25May '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$65.72B$65.50B$67.23B$69.75B$72.47B$68.49B$71.67BPending
Estimate$63.44B$60.20B$62.91B$67.58B$70.31B$66.29B$70.14B$72.65B
Surprise+3.6%+8.8%+6.9%+3.2%+3.1%+3.3%+2.2%—
Estimate$7.51
ReportedDue Oct 29, 2026
Estimate$72.65B
ReportedDue Oct 29, 2026
View details

Debt to equity74.80%
Current ratio84.60%

ProfitabilityRevenueNet incomeNet margin

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue$63.69B$65.65B$65.50B$67.23B$69.75B$72.47B$68.49B$71.67B
Net income$739.0M$1.42B$1.32B$1.53B$1.87B$1.23B$1.65B$1.66B
Net margin1.2%2.2%2.0%2.3%2.7%1.7%2.4%2.3%

GrowthOperating income

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Operating income$2.58B$2.17B$1.97B$2.43B$2.58B$2.15B$2.36B$2.68B
YoY growth+15.0%+5.5%−12.6%+0.8%+0.1%−1.2%+19.6%+10.0%

Balance sheet, Jun 30, 2026Cash & short-term investments $6.30B · Total debt $31.88B · Total assets $157.08B · Shareholders' equity $42.62B

Revenue
$71.67B
Operating income
$2.68B
Net income
$1.66B
View details

Dividend yield
2.26%
Next ex-date
Dec 8, 26
estimated · in 77 days
Annual dividend
$6.19
per share
Schedule
Quarterly
4 payments a year

HistoryDividendAnnual yield

Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Dividend$1.40$1.51$1.51$1.51$1.51$1.56$1.56$1.56
Annual yield1.70%1.84%1.87%1.95%2.25%2.17%2.19%2.24%
Ex-dateDec 4Mar 5Jun 3Sep 4Dec 4Mar 5Jun 4Sep 8
Payment dateDec 19Mar 20Jun 18Sep 18Dec 18Mar 19Jun 18Sep 23
View details

Institutions90.62%239.47M shares
1,766 holders · as of Jun 30, 2026
Insiders0.23%601.4K shares
27 holders · as of Sep 8, 2026
Other9.15%24.17M shares
remainder

264.24M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesDate
BlackRock, Inc.Institution
8.87%23.44Mas of Jun 30, 2026
Vanguard Capital Management LLCInstitution
6.54%17.28Mas of Jun 30, 2026
State Street CorpInstitution
4.80%12.68Mas of Jun 30, 2026
Dodge & CoxInstitution
4.61%12.17Mas of Jun 30, 2026
Massachusetts Financial Services Co /MA/Institution
3.95%10.44Mas of Jun 30, 2026

Insider tradesForm 4

DateInsiderRoleSharesAvg price
Sep 3, 2026Everett Nevilleofficer: See Remarks−617$284.05
Aug 18, 2026Nicole S. Jonesofficer: See Remarks−2,677$279.61
Aug 4, 2026Nicole S. Jonesofficer: See Remarks−19,436$276.27
Jun 12, 2026Jamie G. Katesofficer: Chief Accounting Officer−899$298.61
May 12, 2026David Cordanidirector, officer: Chairman & CEO−201,878$292.82
View details

  • UnitedHealth Group

    Largest U.S. health insurer and PBM — rival across both Cigna segments.

  • CVS Health

    Parallel vertical integrator — Caremark PBM and Aetna rival both Cigna segments.

  • Elevance Health

    Second-largest commercial insurer; CarelonRx PBM adds adjacent rivalry.

  • Humana

    Medicare-focused insurer; employer commercial and CenterWell pharmacy overlap.

Compare

CompanyPriceChange
Cigna$273.42−0.38%$72.53B11.48.60.3+6.6%
UnitedHealth Group$373.54−1.06%$342.88B24.317.50.8+0.4%
CVS Health$87.06−0.62%$111.77B23.210.80.3+7.3%
Elevance Health$402.88−1.57%$88.77B18.214.80.4+0.8%
Humana$372.45−1.62%$45.39B35.930.20.3+26.2%
Median23.716.20.4+4.0%